Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRIMAD: Postoperative FOLFIRI in Colorectal Liver Metastases
NCT06501482Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Nanoparticles, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, folinic acid, fluorouracil in colorectal liver metastases (CRLM), sponsored by Assistance publique - Hôpitaux de Paris. Started Jun 2025; status: recruiting.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfolinic acidfluorouracil
03
Conditions
colorectal liver metastases (CRLM)
Beyond the preview
Go deeper on NCT06501482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06501482.